U.S., Sept. 18 -- ClinicalTrials.gov registry received information related to the study (NCT07177469) titled 'UBT251 Injection Phase II Study (Overweight or Obesity)' on Sept. 01.
Brief Summary: This randomized, double-blind, parallel, placebo-controlled phase II study to evaluate the efficacy and safety of UBT251 Injection in overweight/obese patients
Study Start Date: March 10
Study Type: INTERVENTIONAL
Condition:
Obesity &Amp; Overweight
Intervention:
DRUG: UBT251 Injection 2.0 mg and UBT251 Injection Placebo
UBT251 Injection and UBT251 Injection Placebo subcutaneously once weekly
DRUG: UBT251 Injection 4.0 mg (ID 0.5 mg) and UBT251 Injection Placebo
UBT251 Injection and UBT251 Injection Placebo subcutaneously once weekly
DRUG...